DLBCL
Clinical trials for DLBCL explained in plain language.
Never miss a new study
Get alerted when new DLBCL trials appear
Sign up with your email to follow new studies for DLBCL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for aggressive lymphoma: triple-drug combo enters human trials
Disease control Not yet recruitingThis study tests a new combination of drugs for adults with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to previous treatment. About 46 participants will receive an experimental drug (EZH2 inhibitor) along with two other drugs (glofitamab and chemoth…
Matched conditions: DLBCL
Phase: PHASE1, PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug cocktail aims to tackle tough lymphoma
Disease control Not yet recruitingThis early-stage trial tests a new drug called rocbrutinib combined with standard chemotherapy (R-GemOx) in 42 people with a type of lymphoma (DLBCL) that has returned or not responded to treatment. The main goals are to find a safe dose and see if the combination shrinks tumors.…
Matched conditions: DLBCL
Phase: PHASE1 • Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Gut check: could your microbiome boost lymphoma therapy?
Knowledge-focused Not yet recruitingThis study looks at whether the bacteria living in your gut can influence how well a drug called glofitamab works against diffuse large B-cell lymphoma (DLBCL). Researchers will collect stool samples from 30 patients before and after treatment to track changes in gut microbiome a…
Matched conditions: DLBCL
Sponsor: Peking Union Medical College Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC